| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
56,200,000 |
| Market
Cap: |
281.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.13 - $7.84 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15 |
| Insider 3/6 Months : 15.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and diseases resulting from mutations of a single gene, also known as monogenic diseases, and building a clinical stage pipeline of gene control medicines. Co.'s primary product candidates are: Tamibarotene, which is a selective retinoic acid receptor alpha agonist that is being evaluated in combination with azacitidine; SY-2101, which is an oral form of arsenic trioxide; and SY-5609, which is a selective oral inhibitor of cyclin-dependent kinase 7 that is being evaluated in combination with chemotherapy in relapsed/refractory metastatic pancreatic cancer patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
904,977 |
904,977 |
921,909 |
| Total Buy Value |
$0 |
$3,999,998 |
$3,999,998 |
$4,105,954 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
3 |
| Total Shares Sold |
10,601 |
23,175 |
31,212 |
31,212 |
| Total Sell Value |
$52,479 |
$108,434 |
$139,871 |
$139,871 |
| Total People Sold |
1 |
1 |
2 |
2 |
| Total Sell Transactions |
2 |
4 |
6 |
6 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Eckhardt Sue Gail |
Director |
– • – |
2022-09-16 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
8,000 |
|
- |
|
| Simonian Nancy A |
President & CEO |
• • – |
2022-04-01 |
4 |
D |
$1.12 |
$65,949 |
D/D |
(58,883) |
692,723 |
|
- |
|
| Stephens Kristin |
Chief Development Officer |
• – – |
2022-04-01 |
4 |
D |
$1.12 |
$15,809 |
D/D |
(14,115) |
30,885 |
|
- |
|
| Roth David |
Chief Medical Officer |
• – – |
2022-04-01 |
4 |
D |
$1.12 |
$30,555 |
D/D |
(27,281) |
59,719 |
|
- |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2022-04-01 |
4 |
D |
$1.12 |
$30,538 |
D/D |
(27,266) |
59,734 |
|
- |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2022-01-05 |
4 |
AS |
$3.47 |
$7,655 |
D/D |
(2,208) |
0 |
|
-78% |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2021-07-01 |
4 |
AS |
$5.55 |
$6,460 |
D/D |
(1,164) |
0 |
|
-23% |
|
| Stephens Kristin |
Chief Development OfficerOffic |
• – – |
2021-06-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
45,000 |
|
-27% |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2021-03-15 |
4 |
AS |
$9.47 |
$34,372 |
D/D |
(3,628) |
0 |
|
-50% |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2021-03-15 |
4 |
OE |
$1.01 |
$3,664 |
D/D |
3,628 |
3,628 |
|
- |
|
| Young Richard A |
Director |
– • – |
2021-02-16 |
4 |
AS |
$12.05 |
$45,188 |
D/D |
(3,750) |
321,711 |
|
-54% |
|
| Young Richard A |
Director |
– • – |
2021-02-08 |
4 |
AS |
$13.04 |
$48,900 |
D/D |
(3,750) |
325,461 |
|
-56% |
|
| Simonian Nancy A |
President & CEO |
• • – |
2020-12-18 |
4 |
OE |
$3.04 |
$203,612 |
D/D |
29,917 |
563,606 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
625,000 |
1,899,616 |
|
- |
|
| Young Richard A |
Director |
– • – |
2020-11-17 |
4/A |
AS |
$8.75 |
$46,874 |
D/D |
(5,357) |
329,211 |
|
- |
|
| Young Richard A |
Director |
– • – |
2020-11-17 |
4 |
AS |
$8.75 |
$46,874 |
D/D |
(5,357) |
339,211 |
|
-13% |
|
| Young Richard A |
Director |
– • – |
2020-11-16 |
4/A |
AS |
$8.98 |
$5,684 |
D/D |
(633) |
334,568 |
|
- |
|
| Young Richard A |
Director |
– • – |
2020-11-16 |
4 |
AS |
$8.98 |
$5,684 |
D/D |
(633) |
344,568 |
|
-13% |
|
| Young Richard A |
Director |
– • – |
2020-10-19 |
4 |
AS |
$8.75 |
$49,639 |
D/D |
(5,673) |
335,201 |
|
12% |
|
| Young Richard A |
Director |
– • – |
2020-10-15 |
4 |
AS |
$8.75 |
$2,774 |
D/D |
(317) |
340,874 |
|
8% |
|
| Young Richard A |
Director |
– • – |
2020-09-15 |
4 |
AS |
$10.39 |
$62,236 |
D/D |
(5,990) |
341,191 |
|
0% |
|
| Akkaraju Srinivas |
Director |
– • – |
2020-08-18 |
4 |
AS |
$13.10 |
$2,076,724 |
I/I |
(158,583) |
1,274,616 |
|
-14% |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2020-08-18 |
4 |
AS |
$13.00 |
$140,231 |
D/D |
(10,787) |
0 |
|
-14% |
|
| Olson Eric R |
Chief Scientific Officer |
• – – |
2020-08-18 |
4 |
OE |
$1.01 |
$10,895 |
D/D |
10,787 |
10,787 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2020-08-17 |
4 |
AS |
$13.00 |
$9,672 |
I/I |
(744) |
1,433,199 |
|
-12% |
|
157 Records found
|
|
Page 3 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.2%) 
